| HOME >> BIOLOGY >> TECHNOLOGY |
2006 2007 2006 2007
(Unaudited)
Revenue
License and research fees $ 5,130 $ 1,792 $ 22,667 $ 11,197
Government grants 383 105 383 307
Product revenue 32 -- 624 245
Total revenue 5,545 1,897 23,674 11,749
Operating expenses:
Cost of product revenue 13 -- 314 68
Research and development 10,483 13,774 31,050 39,412
Selling, general and
administrative 3,447 5,090 10,529 14,490
Total operating expenses 13,943 18,864 41,893 53,970
Loss from operations (8,398) (16,967) (18,219) (42,221)
Other income (expense):
Interest income 751 817 2,107 2,722
Interest and other expense (161) (300) (394) (858)
Loss before cumulative effect of (7,808) (16,450) (16,506) (40,357)
change in accounting principle
Cumulative effect of change in
accounting principle -- -- 291 --
Net Loss $(7,808) $(16,450) $(16,215) $(40,357)
Basic and diluted net loss per
share:
Prior to cumulative effect of
change in accounting
principle $ (0.36) $ (0.66) $ (0.78) $ (1.62)
Cumulative effect of change in
accounting principle -- -- 0.01 --
Net loss per common share -
basic and diluted $ (0.36) $ (0.66) $ (0.77) $ (1.62)
Shares used in computing net
loss per share - basic and
diluted
'/>"/>
| SOURCE Nastech Pharmaceutical Company Inc. Copyright©2007 PR Newswire. All rights reserved |